← Back to Search

Other

Azeliragon for Glioblastoma

Phase 2

Recruiting

Research Sponsored by Cantex Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is studying a new treatment for a type of brain cancer that has no cure. Surgery, radiation, and chemo may help, but new treatments are needed.

Who is the study for?

Adults with a specific brain cancer called glioblastoma that hasn't spread, who haven't had certain other cancers or treatments, and whose major organs are functioning well. They must have had surgery for tumor removal but not just a needle biopsy. Participants need to be able to follow the study plan and agree to use birth control if they can have children.Check my eligibility

What is being tested?

The trial is testing Azeliragon combined with radiation therapy as an initial treatment for glioblastoma without MGMT promoter methylation. It's in phase 2, which means it's checking safety and how well it might work after showing promise in earlier research.See study design

What are the potential side effects?

Specific side effects of Azeliragon aren't listed here, but common ones from similar treatments include fatigue, nausea, headaches, and potential allergic reactions. Side effects from radiation may include skin irritation at the treatment site and tiredness.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression-free survival

Secondary outcome measures

Overall survival

Response rate

Steroid requirement

Trial Design

1Treatment groups

Experimental Treatment

Group I: Daily oral azeliragonExperimental Treatment1 Intervention

Azeliragon to be administered once daily for several days before, during, and after radiation therapy.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cantex PharmaceuticalsLead Sponsor

12 Previous Clinical Trials

336 Total Patients Enrolled

2 Trials studying Glioblastoma

41 Patients Enrolled for Glioblastoma

Medpace, Inc.Industry Sponsor

94 Previous Clinical Trials

29,585 Total Patients Enrolled

Stephen G Marcus, MDStudy ChairCantex Pharmaceuticals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA granted approval for daily azeliragon administered orally?

"Our team at Power assigned a score of 2 to daily oral azaliragon as its safety has been supported by clinical evidence, although efficacy still needs to be established."

Answered by AI

Are new participants being accepted for this investigation currently?

"According to the clinicaltrials.gov listing, this medical trial initiated on September 12th 2023 and remains open for participant enrollment. The study post was last modified on October 25th 2023."

Answered by AI

Could you provide a tally of all participants in this clinical experiment?

"Confirmed. Per the information on clinicaltrials.gov, this medical trial is actively searching for volunteers to enroll in their program. It was first posted on September 12th 2023 and has since been updated as recently as October 25th 2023. They are hoping to recruit 30 individuals at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Azeliragon in MGMT Unmethylated Glioblastoma

2023. "Azeliragon in MGMT Unmethylated Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05986851.

All > Glioblastoma New York